Company
ASX:NVU
EMASS, a Nanoveu business, is a fabless semiconductor company specialising in ultra-low-power, AI-enabled system-on-chip (SoC) solutions for always-on sensing and intelligent processing at the edge. Its ECS-DoT architecture enables real-time AI inference at milliwatt-level power, supporting next-generation applications across drones, wearables, hearables, smart devices, industrial IoT, robotics and autonomous systems.
29 stories
The Nanoshield™ protectors are customised to fit the Nescafé touch screen and touchpad coffee machines, and will also be available for 'We Proudly Serve Starbucks®' coffee in selected markets.
The company is confident the distribution agreements will not only help in increasing its avenues to sales but also build recognition among the clients of these distributors.
The company’s antiviral technology has been independently demonstrated to be a highly effective agent for the eradication of viruses and has been proven to eliminate 99.99% of OC43, a viral strain affecting humans that is also a surrogate f
In 2020, the company launched an impressive new prototype that allows people suffering from farsightedness to view a 14-inch screen without glasses.
The Nanoshield product, launched in 2020, has been confirmed to provide exceptional antiviral protection outdoors.
The agreement, which accelerates the availability and reach of Nanoshield products across the UK, is effective immediately and incentivises sales through a series of purchase order targets.
Nanoveu also produces EyeFly3D, which converts 2D digital displays into 3D without the need for 3D glasses and is currently available for Apple iPhones and Google Pixel 3 phones.
The company develops a range of products for mobile phones and other digital displays with its flagship product, Nanosheild, available in a variety of mobile screen covers, phone cases and as a commercial film capable of being applied to se
The placement firms up the balance sheet and ensures the company is able to fully focus on securing international distribution agreements for antiviral products, and advance development of the EyeFyx prototype.
The placement firms up the balance sheet and ensures the company is able to fully focus on securing international distribution agreements for antiviral products, and advance development of the EyeFyx prototype.
The trading halt will remain in place until Friday, December 11, or when an announcement is released to the market.
The agreement marks an expansion of distribution capabilities throughout Australia and a new market in New Zealand, which NVU had not previously targeted for product distribution.
The latest EyeFyx prototype is aimed at improving access to digital devices for people suffering from farsightedness.
During the September quarter, the company appointed several new distributors across many regions and secured sales orders of around $250,000 for its B2B antiviral film and antiviral mobile phone protection products.
Sales to Vietnam add to Nanoveu’s growing order book with customers in Australia, Malaysia, Singapore, Thailand, UK, and USA.
Unless ASX decides otherwise, the securities will remain halted until the start of normal trading on Thursday, September 24, or when an announcement is released to the market.
The funding will go towards commercialisation of the company’s new business lines in antiviral screen protector technology and laminating machines.
The company has recently signed agreements with Sanyo Trading Company Ltd for exclusive distribution of its antiviral products.
The company has signed agreements with Sanyo Trading Company Ltd for exclusive distribution of its antiviral products.
The company is confident of strong demand for its products, with orders from customers across the US, UK, Asia and Australia.
The agreement will expand the application of Nanoveu’s antiviral technology through the sale of antiviral gym and home fitness equipment to the Asia-Pacific region.
An agreement has been signed with a subsidiary of major Thai telecommunications network AIS to deploy Customskins laminating machines.
D360 will assist in online retail sales as well as go-to-market services for the US, Canada and UK regions
The Australian Therapeutics Goods Administration has registered the technology as a Class I Medical Device.
In just 30 minutes the number of viable or infectious coronavirus particles was reduced by 99.99%.
The antimicrobial technology demonstrated to be effective against a coronavirus strain emerging from mice, which is a surrogate for human coronaviruses.
The company has developed antiviral nanotechnology to deliver enhanced protection from viruses and bacteria for smartphone and tablet users.
The company’s nanotechnology is being developed to protect phone and tablet users from viruses and bacteria, including coronavirus.
Initial testing has demonstrated Nanoveu’s technology to be effective against viruses and bacteria.
